New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a leading venture capital and growth equity firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With approximately $17 billion in committed capital, NEA invests in information technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions. In the U.S., NEA has offices in Menlo Park, CA; New York, NY; and the Washington, D.C. metropolitan area. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.
Johnson & Johnson Innovation – JJDC, Inc.
Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. The firm has approximately $350 million under management in five venture capital funds. Hatteras is led by a seasoned team of entrepreneurs and operators and has a long and successful track record of seed and early stage investing and company formation.
Fletcher Spaght Ventures
Fletcher Spaght Ventures, L.P. (FSV) is a venture capital firm investing in emerging growth healthcare and high technology companies. FSV invests as a lead and co-investor, collaborating with other leading venture capital firms. As value added investors, FSV brings to bear the resources of its consulting division, Fletcher Spaght, Inc., which focuses on board-level, pre-commercialization intelligence for start-ups, and market and due diligence assignments for larger corporations. FSV has two funds under management totaling $120 million with investments nationwide.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Astellas Venture Management
Syno Capital is a global cross border venture capital firm dedicated to life science and healthcare. Aside from being resourceful in the United States, it provides help to its portfolio companies in expanding into the Greater China region. Syno Capital has extensive experience in building partnerships in China and its network of strategic partners can accelerate the growth of companies both domestically and internationally.